Atrial fibrillation patient information management and service system based on Internet and method

Abstract

The invention belongs to the field of medical technology, and discloses an atrial fibrillation patient information management and service system based on Internet and a method. The atrial fibrillationpatient information management and service system comprises the components of an application layer, an official account service management terminal and a database server. The application layer is thefirst layer and is used for supporting a PC computer terminal and mobile equipment. A patient and medical personnel enters a medical communication system through a Wechat official account platform. The system mainly performs data browsing, inquiring, recording of a small number of texts or image uploading in modes such as online H5 PAGE. The official account service management terminal is a second layer and is used for receiving a client request, performing exchange with a background server, generating information according to service logic and transmitting the information to the H5 page fordisplaying. The database server is a third layer and is used for organizing and storing data such as patient information, medicine information, treatment result information and knowledge database.

Description

technical field [0001] The invention belongs to the field of medical technology, and in particular relates to an internet-based information management and service system and method for patients with atrial fibrillation. Background technique [0002] Currently, the closest prior art: [0003] Atrial fibrillation (AF; atrial fibrillation for short) is the second most common cardiovascular disease after coronary heart disease in incidence, and its related stroke is the main complication of disability and death, seriously affecting the quality of life of patients. According to the 2017 Global Burden of Disease Survey, 30% of clinical ischemic strokes are caused by atrial fibrillation, and its disease burden is 55.1 million disability-adjusted life-years (DALYs), accounting for the third place in the burden of cardiovascular disease. bit. The disease burden of atrial fibrillation in China is far heavier than that in European and American countries, and its incidence rate has in...

AI Technical Summary

Problems solved by technology

Preliminary investigations found that: as a tertiary hospital, 16% of patients with atrial fibrillation in our hospital did not use anticoagulant drugs, and the anticoagulant compliance rate was less than 50%. It is the main factor affecting the choice of anticoagulant drug therapy for patients in our hospital

[0006] Anticoagulant drug therapy lacks a standardized management system—the classic anticoagulant drug warfarin has shortcomings such as narrow therapeutic window, large dose variability, easy interaction with other drugs and food, and the need for laboratory monitoring. Patients who receive warfarin often Frequent monitoring of anticoagulant indicators and dosage adjustment is required, which takes more time and energy, greatly reduces the patient's medication and monitoring compliance (especially for patients who are older and have many comorbid diseases), resulting in a lower rate of anticoagulant compliance and potential thrombosis / increased risk of bleeding;

[0007] Lack of sufficient evidence-based evidence for new anticoagulants—New oral anticoagulants (Novel Oral Anticoagulants, NOACs, including dabigatran, rivaroxaban, apixaban, and edoxaban) have been on the market in China for less than 5 years. It was included in the scope of medical insurance payment in 2018, and the clinical experience is limited; the Chinese population and special populations lack sufficient evidence-based evidence to support clinical use, resulting in violations of contraindications, improper selection of varieties, insufficient or excessive doses, etc., which directly affect anticoagulant therapy safety and efficacy

[0012] (1) Anticoagulant drug treatment lacks a standardized management system, and new anticoagulant drugs lack sufficient evidence-based evidence

[0013] (2) The existing intervention methods are inefficient, with high time and labor costs, and high loss-to-follow-up rate. There is no statistical difference in the anticoagulation compliance rate and clinical endpoint events, and there is a lack of reliable evidence to prove the effectiveness of the intervention method

[0014] (3) There is currently a lack of standardized anticoagulant drug management for atrial fibrillation in China, and there is a shortage of disease management personnel in primary medical institutions

Images